Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
02:30am, Thursday, 04'th Dec 2025
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
01:46pm, Wednesday, 03'rd Dec 2025
Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
01:00pm, Wednesday, 03'rd Dec 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigati
Why Bayer Aktiengesellschaft (BAYRY) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 03'rd Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today
10:25am, Tuesday, 02'nd Dec 2025
Shares of pharmaceutical conglomerate Bayer (BAYRY) are surging 12% on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review prior ruli
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
08:05am, Tuesday, 02'nd Dec 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intraute
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
06:00am, Tuesday, 02'nd Dec 2025
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverG
Bayer stock has its best day in 17 years after support from Trump's solicitor general
03:52am, Tuesday, 02'nd Dec 2025
Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company's bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.
Trump administration backs Bayer's bid to curb Roundup lawsuits
07:35pm, Monday, 01'st Dec 2025
President Donald Trump's administration urged the U.S. Supreme Court on Monday to take up Bayer's bid to curtail thousands of lawsuits claiming its Roundup weedkiller causes cancer, backing the compan
Bayer Welcomes Solicitor General Support for U.S. Supreme Court Review
07:13pm, Monday, 01'st Dec 2025
LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer is pleased the Solicitor General supports U. S. Supreme Court review of the petition for a writ of certiorari in the Durnell case and agrees with the compan
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
10:41am, Monday, 01'st Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Market Today: Alphabet rallies, Amazon's $50B AI push
05:35pm, Monday, 24'th Nov 2025
Guru Stock PicksElfun Trusts has made the following transactions:Reduce in MLM by 7.18%Sold out in KVUEAdd in TXN by 36.84%New position in AMDStock News Tech-le
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
02:56pm, Monday, 24'th Nov 2025
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
01:14pm, Monday, 24'th Nov 2025
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.
